Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary ...

Gray hair is nothing to be ashamed of. In fact, according to a new study by researchers in Japan, the presence of gray hair ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc ...

EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...

Discover how the Amazon’s purple powerhouse, the açaí berry, is being redefined by science for its role in combating ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nexxen (NASDAQ: NEXN), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced it has licensed its ...

This review highlights hydroxytyrosol's role as a neuroprotective agent, activating key pathways for mental and vascular ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guide ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...